For example, a previous in silico study showed that an intermittent abiraterone followed by a lead-in period was not beneficial for prostate cancer patients, and the adaptive intermittent treatment guided by PSA was demonstrated to be the best option19. This evidence concerns the gene KLK3 and prostate cancer.